Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03241810
Recruitment Status : Terminated (Merrimack Inc. terminated the trial early due to business decision)
First Posted : August 8, 2017
Results First Posted : September 2, 2020
Last Update Posted : September 2, 2020
Sponsor:
Information provided by (Responsible Party):
Elevation Oncology

Tracking Information
First Submitted Date  ICMJE August 2, 2017
First Posted Date  ICMJE August 8, 2017
Results First Submitted Date  ICMJE July 20, 2020
Results First Posted Date  ICMJE September 2, 2020
Last Update Posted Date September 2, 2020
Actual Study Start Date  ICMJE August 15, 2017
Actual Primary Completion Date November 30, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 7, 2020)
Progression Free Survival [ Time Frame: Randomization until progression of disease or death due to any cause up to 13 months (The study terminated prematurely) . The primary analysis was planned to be initiated when 58 PFS events have occurred ]
Progression Free Survival is defined as the time from randomization to the first documented radiographical progression of disease using RECIST v1.1 or death from any cause, whichever comes first as assessed by the investigator. The tumor assessment (i.e., scan dates) was used for progression/censor date not the date corresponding to the determination of overall response. Progression-free survival time distribution and median survival for each treatment group were analyzed using the Kaplan-Meier method.
Original Primary Outcome Measures  ICMJE
 (submitted: August 7, 2017)
Progression Free Survival [ Time Frame: A total study duration of approximately 20 months is expected. The primary analysis will be initiated when 58 PFS events have occurred ]
Time from randomization to disease progression according to RECIST v 1.1 as assessed by the Investigator
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 20, 2020)
  • Overall Survival [ Time Frame: Randomization until death due to any cause up to 13 months (The study terminated prematurely) ]
    Overall Survival (OS) is defined as the time from the date of randomization to the date of death from any cause. The study was terminated on 30 Nov 2018 . Data represents outcomes up to 150 days of treatment.
  • Objective Response Rate [ Time Frame: Randomization through end of study up to 13 months (The study terminated prematurely) ]
    Objective Response Rate (ORR) is defined as the proportion of patients with a RECIST v1.1 response recorded from randomization until disease progression characterized as either a Complete Response (CR) or Partial Response (PR) relative to the total number of evaluable patients.
  • Time to Progression [ Time Frame: Randomization to date of objective tumor progression up to 13 months (The study terminated prematurely) ]
    Time to Progression (TTP) is defined as the time from the date of randomization to the date of objective tumor progression.
  • Number of Participants With Treatment-emergent Adverse Events Reported With the Combinations of Seribantumab Plus Fulvestrant Versus Fulvestrant Alone [ Time Frame: TEAEs were collected through the study completion (30 Nov 2018), up to 13 months. Frequency and percent summaries were presented for TEAE defined as adverse events that occur or worsen in severity following the first dose of seribantumab, or fulvestrant ]
    Treatment-emergent adverse events (TEAEs) are defined as any event that occurred after the first dose of study drug and was not present prior to study drug administration or worsened in severity after study drug administration.
  • Percentage of Treatment-emergent Adverse Events Reported With the Combinations of Seribantumab Plus Fulvestrant Versus Fulvestrant Alone [ Time Frame: TEAEs were collected through the study completion (30 Nov 2018), up to 13 months. Frequency and percent summaries were presented for TEAE defined as adverse events that occur or worsen in severity following the first dose of seribantumab, or fulvestrant ]
    Treatment-emergent adverse events (TEAEs) are defined as any event that occurred after the first dose of study drug and was not present prior to study drug administration or worsened in severity after study drug administration.
  • Pharmacokinetic (PK) Profile of Seribantumab When Given in Combination With Fulvestrant and of Fulvestrant When Given in Combination With Serbantumab. [ Time Frame: The study terminated prematurely after 13 months. Were to be analyzed post-dose on Cycle 1,Week 1 & pre-dose for all subsequent seribantumab infusions until the completion of Cycle 2. Fulvestrant PK samples were to be collected prior to seribantumab dose ]
    Pharmacokinetic (PK) evaluation are performed on samples obtained pre-dose on day 1 and 15 of each 28-day cycle to assess pre-treatment trough concentrations of MM-121. The maximum observed concentration (Cmax) is presented and calculated usig Non-compartmental analysis (NCA). Serum levels of MM-121 are measured at a central lab using an enzyme-linked immunosorbent assay (ELISA).
Original Secondary Outcome Measures  ICMJE
 (submitted: August 7, 2017)
  • Overall Survival [ Time Frame: A total study duration of approximately 20 months is expected. ]
    Time from randomization to death
  • Objective Response Rate [ Time Frame: A total study duration of approximately 20 months is expected. ]
    Based on RECIST v 1.1
  • Time to Progression [ Time Frame: A total study duration of approximately 20 months is expected. ]
  • Rate of Treatment-emergent Adverse Events Reported With the Combinations of Seribantumab Plus Fulvestrant Versus Fulvestrant Alone [ Time Frame: A total study duration of approximately 20 months is expected. ]
  • Pharmacokinetic (PK) Profile of Seribantumab When Given in Combination With Fulvestrant and of Fulvestrant When Given in Combination With Serbantumab. [ Time Frame: A total study duration of approximately 20 months is expected. ]
    Pharmacokinetic (PK) evaluation will be performed on samples obtained pre-dose on day 1 and 15 of each 28-day cycle to assess pre-treatment trough concentrations of MM-121. The maximum observed concentration (Cmax) will be presented and will be calculated usig Non-compartmental analysis (NCA). Serum levels of MM-121 will be measured at a central lab using an enzyme-linked immunosorbent assay (ELISA).
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
Official Title  ICMJE Randomized Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)
Brief Summary This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer.
Detailed Description This study is a randomized, double-blind, placebo-controlled international phase 2 trial in patients with HRG+, HR+, HER2- metastatic breast cancer that has progressed following treatment with no more than 2 prior therapies, one of which must have been a CDK inhibitor. All patients will be screened for heregulin using central testing, and eligible patients will be randomized to receive either seribantumab + fulvestrant or placebo + fulvestrant. Disease status will be assessed according to RECIST v 1.1 to support the primary endpoint.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Patients will be randomized in a 1:1 ratio (experimental arm versus active comparator arm) using an Interactive Web Response System (IWRS). Randomization will be stratified based on bone-only disease (yes, no) and geographic region (US, non-US).
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:
This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 Study.
Primary Purpose: Treatment
Condition  ICMJE Metastatic Breast Cancer
Intervention  ICMJE
  • Drug: Seribantumab
    Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling
    Other Name: MM-121
  • Drug: Fulvestrant
    Fulvestrant is an estrogen receptor antagonist with no agonist effects
    Other Name: Faslodex
  • Drug: Placebo
    Placebo
    Other Name: Solution containing 20 mM histidine, 150 mM sodium chloride, at a pH of 6.5
Study Arms  ICMJE
  • Experimental: Arm A

    Seribantumab

    Fulvestrant

    Interventions:
    • Drug: Seribantumab
    • Drug: Fulvestrant
  • Active Comparator: Arm B

    Placebo

    Fulvestrant

    Interventions:
    • Drug: Fulvestrant
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: November 5, 2019)
22
Original Estimated Enrollment  ICMJE
 (submitted: August 7, 2017)
80
Actual Study Completion Date  ICMJE November 30, 2018
Actual Primary Completion Date November 30, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

To be eligible for participation in the study, patients must meet the following criteria. Patients who are HRG negative do not need to complete screening procedures beyond HRG assessment.

  1. Patients must have histologically or cytologically confirmed ER+ and/or PR+ (with staining of >1% cells) breast cancer.
  2. Patients with confirmed postmenopausal status due to either surgical/natural menopause or ovarian suppression.
  3. Patients must be HER2 negative.
  4. Patient must have at least one lesion amenable to either core needle biopsy or fine needle aspiration.
  5. Patient must have a positive in-situ hybridization (ISH) test for heregulin, as determined by centralized testing of unstained tumor tissue.
  6. Patients that have progressed following at least one but no more than two prior systemic therapies in the locally advanced or metastatic disease setting.
  7. Patients with documented progression of locally advanced or metastatic disease as defined by RECISTv1.1 (Exception: patients with bone-only metastatic disease are eligible if they have at least 2 lytic lesions visible on a CT or MRI and have documented disease progression on prior therapy based on the appearance of new lesions).
  8. Patients with bone-only lesions who have received radiation to those lesions must have documented progression following radiation therapy.
  9. ECOG Performance Score (PS) of 0 or 1.
  10. Patients with adequate bone marrow reserves.
  11. Adequate hepatic function.
  12. Adequate renal function.
  13. Patient has recovered from clinically significant effects of any prior, surgery, radiosurgery, or other antineoplastic therapy.
  14. Patients who have experienced a venous thromboembolic event within 60 days of signing the main consent form should have been treated with anti-coagulants for at least 7 days prior to beginning treatment and for the duration of treatment on this study.

Exclusion Criteria:

Patients must meet all the inclusion criteria listed above and none of the following exclusion criteria.

  1. Prior treatment with an anti-ErbB3 antibody.
  2. Prior treatment with a chemotherapy in the locally advanced or metastatic disease setting.
  3. Patients cannot have received prior treatment with fulvestrant or other SERDs in the locally advanced or metastatic setting.
  4. Uncontrolled CNS disease or presence of leptomeningeal disease.
  5. Inflammatory breast cancer.
  6. History of another active malignancy that required systemic therapy in the last 2 years. Patients with prior history of in-situ cancer, basal, or squamous cell skin cancer are eligible.
  7. Patients with an active infection, or unexplained fever > 38.5 C during screening visits or on the first scheduled day of dosing, which in the investigator's opinion might compromise the patients participation in the trial or affect the study outcome. At the discretion of the investigator, patients with tumor fever may be enrolled.
  8. Known hypersensitivity to any of the components of seribantumab, fulvestrant, or who have had hypersensitivity reactions to fully human monoclonal antibodies.
  9. NYHA Class III or IV congestive heart failure.
  10. Patients with a significant history of cardiac disease (i.e. uncontrolled blood pressure, unstable angina, myocardial infarction within 1 year or ventricular arrhythmias requiring medication) are also excluded.
  11. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; or active human immunodeficiency virus (HIV) infection, active hepatitis B infection or active hepatitis C infection.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Gender Based Eligibility: Yes
Gender Eligibility Description: Confirmed postmenopausal status due to either surgical/natural menopause or ovarian suppression (initiated at least 28 days prior to Day 1 of Cycle 1).
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Belgium,   Canada,   Germany,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03241810
Other Study ID Numbers  ICMJE MM-121-02-02-10
2017-000565-76 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Elevation Oncology
Study Sponsor  ICMJE Elevation Oncology
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Marc Pipas, MD Merrimack Pharmaceuticals Inc.
PRS Account Elevation Oncology
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP